Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Nov;8(11):1807-13.
doi: 10.2217/nnm.12.214. Epub 2013 Apr 23.

Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients

Jennifer Williams  1 , Harlan R Sayles, Jane L Meza, Patrick Sayre, Uriel Sandkovsky, Howard E Gendelman, Charles Flexner, Susan Swindells
Affiliations

Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients

Jennifer Williams et al. Nanomedicine (Lond). 2013 Nov.

Abstract

Aim: To gauge patient interest in receiving long-acting injectable nanoformulated antiretroviral therapy.

Methods: Four hundred adult HIV-infected patients currently prescribed antiretroviral therapy were surveyed. χ(2) tests were used for comparisons of interest across groups.

Results: Respondents were 68% male and 53% African-American, with a mean age of 47 years. Overall, 73% of patients indicated that they would definitely or probably try injectable nanoformulated antiretroviral therapy; 61% with weekly dosing; 72% every 2 weekly; and 84% monthly. In total, 48% indicated that they were very concerned about the possible side effects and 35% were very concerned about needle use.

Conclusion: The majority of respondents indicated that they definitely or probably would try parenteral nanoformulated antiretroviral therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Patient interest by timing of injections, respondent demographics and self-reported adherence
Percentages of respondents who indicated that they definitely would, probably would, probably would not or definitely would not be interested in trying nanoformulated parenteral antiretroviral therapy (A) overall, (B) by age, (C) by race or gender and (D) by level of self-reported adherence. The actual number of respondents to each specific question is included in parentheses.
Figure 2
Figure 2. Patient interest by drug use
Percentages of respondents who indicated that they definitely would, probably would, probably would not or definitely would not be interested in trying nanoformulated parenteral antiretroviral therapy by (A) drug use in the previous 6 months and by (B) intravenous drug use in the previous 6 months. The actual number of respondents to each specific question is included in parentheses.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. 2000;133(1):21–30. - PubMed

    1. Swindells S, Flexner C, Fletcher CV, Jacobson JM. The critical need for alternative antiretroviral formulations, and obstacles to their development. J. Infect. Dis. 2011;204(5):669–674. Recent position paper highlighting the need for alternative methods of delivering antiretroviral therapy.

    1. Pautler M, Brenner S. Nanomedicine: promises and challenges for the future of public health. Int. J. Nanomedicine. 2010;5:803–809. - PMC - PubMed

    1. Roy U, Mcmillan J, Alnouti Y, et al. Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice. J. Infect. Dis. 2012;206(10):1577–1588. Results of experiments with nanoformulated antiretroviral agents in mice, demonstrating prolonged antiviral activity.

    1. Balkundi S, Nowacek AS, Veerubhotla RS, et al. Comparative manufacture and cell-based delivery of antiretroviral nanoformulations. Int. J. Nanomedicine. 2011;6:3393–3404. Evaluation of candidate nanoformulated antiretroviral therapy agents, in vitro, outlining the issues concerning drug formulation and composition.

Websites

    1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Department of Health and Human Services; Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. www.aidsinfo.nih.gov/guidelines. Current US treatment guidelines outlining principles of antiretroviral therapy, preferred and alternative treatment regimens, and rationale for their selection.

    1. Second Implementation Report 2007–2009. Communication from the Commission to the Council, the European Parliament and the European Economic and Social Committee; 2009. Nanosciences and nanotechnologies: an action plan for Europe 2005–2009. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2009:0607:FIN:....

Publication types

Substances